Elderly acute myeloid leukemia: Patients are not all the same

Haematologica

Volumn 89, Issue 3, 2004, Pages 261-262

  Schaich, Markus ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANGIOGENESIS INHIBITOR; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLT3 LIGAND; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CLINICAL PROTOCOL; EDITORIAL; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; REMISSION; RISK FACTOR; SURVIVAL;

ACUTE DISEASE; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GENES, MDR; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID; REMISSION INDUCTION;

EID: 2942738762     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (14)

1. Pulsoni A, Pagano L, Latagliata R, Casini M, Cerri R, Crugnola M, et al. Survival of elderly patients with AML. Haematologica 2004;89:296-302.
2. Baudard M, Marie JP, Cadiou M, Viguie F, Zittoun R. Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients. Br J Haematol 1994;86:82-91.
3. Lowenberg B, Zittoun R, Kerkhofs H, Jehn U, Abels J, Debusscher L, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 1989;7:1268-74.
4. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1312-20.
5. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997;89:3323-9.
6. Estey EH. How I treat older patients with AML. Blood 2000;96:1670-73.
7. Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, Makary AZ, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004;103:479-85.
8. Schaich M, Illmer T, Aulitzky W, Bodenstein H, Clemens M, Neubauer A et al. Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years. Haematologica 2002;87:808-15.
9. Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996;88:2841-51.
10. Roboz GJ, Knovich MA, Bayer RL, Schuster MW, Seiter K, Powell BL, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia. Leuk Lymphoma 2002;43:1951-5.
11. Bertz H, Potthoff K, Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol 2003;21:1480-84.
12. Giles FJ, Stopeck AT, Silverman LR, Lancet JE, Cooper MA, Hannah AL, et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 2003;102:795-801.
13. Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001;97:3361-9.
14. Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K, et al. Single agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004 (in press).